Condition: High Titers of Anti-HLA Antibody (MFI ≥5000) · Sponsor: Anhui Provincial Hospital
Evaluation of the efficacy and safety of immunoadsorption or plasma exchange combined with rituximab and high-dose IVIG to reduce high titres of anti-HLA antibodies in patients prior to allogeneic haematopoietic stem cell transplantation
This description comes directly from the study's public registry record.
Xiaoyu Zhu, ph.D. · 15255456091 · xiaoyuz@ustc.edu.cn
Yue Wu, M.D. · 13805601119 · 287109658@qq.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) | Hefei, Anhui, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06362967